Revenue was 21,388 million yen (cumulative Q2 for FY2027, +4.7% YoY), but net income declined sharply to 1,125 million yen. The prior-year period included a one-off special gain, and with that no longer present profits decelerated. The company aims for mid-term growth through ROIC improvement, portfolio review, and strengthened partnerships. Shareholder returns are maintained and a new shareholder benefit program was announced.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4549","jir_company_name":"Eiken Chemical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4549-20261029-02.pdf","jir_short_summary":"Revenue was 21,388 million yen (cumulative Q2 for FY2027, +4.7% YoY), but net income declined sharply to 1,125 million yen. The prior-year period included a one-off special gain, and with that no longer present profits decelerated. The company aims for mid-term growth through ROIC improvement, portfolio review, and strengthened partnerships. Shareholder returns are maintained and a new shareholder benefit program was announced.","jir_summary":"### Performance Overview\nCumulative revenue for Q2 of the fiscal year ending March 2027 was 21,388 million yen (up 4.7% year-on-year), securing revenue growth. However, net income attributable to owners of parent was 1,125 million yen, marking a significant decline due to the absence of the prior-period special gain. By segment, growth was supported by fecal occult blood and tuberculosis gene test reagents and domestic medical devices, while gene-related businesses saw revenue declines due to the domestic infectious disease situation and patent fee impacts. The company is promoting ROIC improvement and CCC optimization.\n\n### Shareholder Returns and Growth Strategy\nThe shareholder return policy will be maintained, and a new shareholder benefit program has been established. Efforts will focus on improving ROIC and advancing the development pipeline, strengthening sales and supply systems through collaborations with Towns and Kyokuto Pharmaceutical Industrial Co., Ltd., and enhancing capital efficiency via CCC improvement. Under the mid-term plan 2030, the company will proceed with launches of new products such as the OC Sensor R70 and FER II to capture domestic and international colorectal cancer screening demand.","jir_financial_highlights":"Revenue: 21,388 (YoY +4.7%)\nOperating Income: 1,587 (YoY -8.2%)\nNet Income Attributable to Owners of Parent: 1,125 (YoY -62.2%)","jir_category":"","jir_hashtags":"#EikenChemical, #Earnings, #ROICImprovement, #Collaboration, #MidtermManagementPlan2030","jir_key_figures":"Revenue: 21,388 million yen\nOperating Income: 1,587 million yen\nNet Income Attributable to Owners of Parent: 1,125 million yen","jir_meta_title":"Eiken Chemical Co., Ltd. Fiscal 2027 Q2 Results | Revenue Up but Profit Slows","jir_meta_description":"Key points of Eiken Chemical's fiscal 2027 Q2 results. Revenue rose 4.7% YoY to 21,388 million yen, while net income decreased to 1,125 million yen. The company is driving growth through ROIC improvement, new product launches, and strengthened collaborations. Shareholder returns are maintained with a new benefit program.","jir_og_title":"Eiken Chemical Co., Ltd. | FY2027 Q2 Results: Revenue Up, Profit Down","jir_og_description":"Summary of Eiken Chemical's Q2 results. Revenue increased while profit declined significantly year-on-year. The company targets mid-term growth through ROIC improvement, new products, and collaborations. Shareholder returns maintained with a new shareholder benefit program announced.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY26 Q2\\\",\\\"FY27 Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[20430,21388]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY26 Q2\\\",\\\"FY27 Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[1729,1587]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY26 Q2\\\",\\\"FY27 Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[2979,1125]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fecal Occult Blood\\\",\\\"Immunoserology\\\",\\\"Urinalysis\\\",\\\"Microbiology\\\",\\\"Clinical Chemistry\\\",\\\"Instruments & Food Environment\\\",\\\"Gene-related\\\",\\\"Medical Devices & Others\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Cumulative Q2 FY27 Results\\\",\\\"data\\\":[725,636,???]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Gross Margin\\\",\\\"Operating Margin\\\",\\\"Ordinary Income Margin\\\",\\\"Net Margin\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Q2 FY27\\\",\\\"data\\\":[37.8,7.4,7.6,5.3]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Comparison of Forecast and Results\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":{\\\"headers\\\":[\\\"Metric\\\",\\\"Actual\\\",\\\"Forecast\\\"],\\\"rows\\\":[[\\\"Revenue\\\",\\\"21,388\\\",\\\"-\\\"],[\\\"Net Income\\\",\\\"1,125\\\",\\\"-\\\"],[\\\"Operating Income\\\",\\\"1,587\\\",\\\"-\\\"]]},\\\"options\\\":{}}\"}]","ir_related_company":16754,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-136031","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n